Quantcast

Latest Cancer vaccine Stories

2014-03-05 11:01:37

Johns Hopkins researchers identify set of genes that can be turned back on and potentially allow for more effective treatment Johns Hopkins researchers say they have identified a set of genes that appear to predict which tumors can evade detection by the body's immune system, a step that may enable them to eventually target only the patients most likely to respond best to a new class of treatment. Immune therapy for ovarian, breast and colorectal cancer — treatments that encourage the...

2014-03-05 10:57:36

An experimental drug aimed at restoring the immune system's ability to spot and attack cancer halted cancer progression or shrank tumors in patients with advanced melanoma, according to a multisite, early-phase clinical trial at Johns Hopkins Kimmel Cancer Center and 11 other institutions. All patients had experienced disease progression despite prior systemic therapies, and most had received two or more prior treatments. Patients who showed responses to the drug, nivolumab (anti-PD-1;...

2014-02-26 20:22:18

DUBLIN, February 26, 2014 /PRNewswire/ -- Dublin - Research and Markets ( http://www.researchandmarkets.com/research/h27svw/flatrate) has announced the addition of the "Flat-Rate Subscription to In-Depth Publishing Reports on Oncology, Biosimilars, Antibodies, Proteins and Vaccines" [http://www.researchandmarkets.com/research/h27svw/flatrate ] subscription to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Subscription to this product...

2014-02-18 04:21:13

New VPs of R&D and Clinical Development add extensive pharmaceutical and biotech immunotherapy product development experience BLUE BELL, Pa., Feb. 18, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced it has expanded its senior management team with two appointments to help advance the company's growing pipeline of preclinical and clinical DNA vaccines. Inovio has appointed Dr. Laurent Humeau as Vice President of R&D and Dr. Jan Marie-Albert Van...

2014-02-14 16:25:28

Featured Talk Emphasizes Importance of Antigen-Specific Dendritic Cell Cancer Vaccines to Generate Powerful T-Cell Response LOS ANGELES, Feb. 14, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that the Company's Founder and Chief Scientific Officer, John S. Yu, MD, delivered a presentation highlighting the therapeutic importance of utilizing antigen-specific dendritic cell (DC) cancer vaccines for inducing a potent T-cell...

2014-02-11 12:26:43

Recurrent lung cancer responds to Integrative Immunotherapy SCOTTSDALE, Ariz., Feb. 11, 2014 /PRNewswire/ -- Lung cancer is the most common cause of cancer-related death worldwide, with the highly malignant small cell lung cancer having the worst prognosis. In recent years the surge of immunotherapy has given cancer sufferers new hope. To view the multimedia assets associated with this release, please visit...

2014-02-06 08:28:58

BETHESDA, Md., Feb. 6, 2014 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that Linda F. Powers, CEO, will present at the BIO CEO and Investor Conference 2014, which is being held in New York on February 10-11, 2014. NW Bio's presentation will take place on Monday, February 10, at 11:30 a.m. EST in the Basildon Room at the Waldorf-Astoria in New York...

2014-02-05 08:28:16

THOUSAND OAKS, Calif., Feb. 5, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Merck, known as MSD outside the United States and Canada, announced today that they have entered into an agreement through a subsidiary to evaluate the safety and efficacy of talimogene laherparepvec, an investigational oncolytic immunotherapy, combined with MK-3475, an investigational anti-PD-1 immunotherapy, in a Phase 1b/2 study of patients with mid- to late-stage melanoma. "Talimogene laherparepvec has...

2014-02-04 12:28:11

WORCESTER, Mass. and TORONTO, Feb. 4, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced that an interview of Dr. Eric von Hofe, PhD, President of the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), conducted by Stock News Now at last month's J.P. Morgan Healthcare Conference in San Francisco, is now available online. The interview is in respect of the ongoing Phase II trial of the Antigen Express...

2014-02-03 08:28:23

DUBLIN, Ireland, February 3, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/v6rrkv/vaccine_market_by) has announced the addition of the "Concise Analysis of the International Vaccine Market - Global Forecasts To 2022" [http://www.researchandmarkets.com/research/v6rrkv/vaccine_market_by ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The global vaccine technology market is...


Word of the Day
baudekin
  • A rich embroidered or brocaded silk fabric woven originally with a warp of gold thread.
'Baudekin' seems to be an alternative form of 'baldachin,' from the Italian 'Baldacco,' Baghdad, the city where the material was made.
Related